Indications And Dose
Hormone-dependent metastatic breast cancer in postmenopausal women ▶BY MOUTH ▶Adult: 60 mg daily
PDF page 1027
Loading InternPractice…
Drug reference
Hormone-dependent metastatic breast cancer in postmenopausal women ▶BY MOUTH ▶Adult: 60 mg daily
PDF page 1027
Bradycardia. electrolyte disturbances (particularly uncorrected hypokalaemia). endometrial hyperplasia. heart failure with reduced left- ventricular ejection fraction. history of arrhythmias. QT prolongation
PDF page 1027
Avoid in Acute porphyrias p. 1120. history of severe thromboembolic disease
PDF page 1027
→Appendix 1: toremifene
PDF page 1027
▶Common or very common Dizziness. fatigue. hot flush. hyperhidrosis. nausea. oedema. skin reactions. vaginal discharge. vomiting ▶Uncommon Appetite decreased. constipation. depression. dyspnoea. headache. insomnia. thromboembolism. uterine disorders. weight increased ▶Rare or very rare Alopecia. corneal opacity. endometrial cancer. hepatic disorders. uterine haemorrhage. vertigo ▶Frequency not known Anaemia. leucopenia. thrombocytopenia SIDE-EFFECTS, FURTHER INFORMATION Increased endometrial changes, including hyperplasia, polyps and cancer reported.
PDF pages 1027, 1028
Avoid.
PDF page 1028
Avoid.
PDF page 1028
Manufacturer advises caution; avoid in severe hepatic failure (risk of decreased elimination).
PDF page 1028
There can be variation in the licensing of different medicines containing the same drug. Tablet ▶Fareston (Orion Pharma (UK) Ltd) Immune system and malignant disease Toremifene (as Toremifene citrate) 60 mg Fareston 60mg tablets | 30 tablet P £29.08 DT = £29.08 HORMONE ANTAGONISTS AND RELATED AGENTS › AROMATASE INHIBITORS
PDF page 1028
60 mg daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1027